



## **Private Health Reform Initiative Working Group Statement**

**Mission:** To inform and develop policies that restore the rights and ability of Americans to control their health finances and make cost-conscious decisions, leading innovators to develop services and products that best meet Americans' needs and improve health care and health.

### **Guiding Principles / Core Values:**

- Empowered individuals with good incentives and accurate information will lead to productivity-enhancing innovation, making health care cheaper, better, and more accessible.
- Americans' general lack of financial control over their health care, combined with a lack of transparency of price and quality, results in significant wasteful spending.
- Excessive bureaucracy—often driven by government—adds unnecessary costs and increases frustration for patients, providers, and nearly every other medical supplier.
- Government often imposes harmful restrictions that prevent providers from best meeting patient needs and from adjusting capacity to meet community needs.
- Innovation should be responsive to real patient needs instead of reacting principally to government reimbursements.

### **Strategic Action Items to Achieve Goals**

#### *Goal 1: Enhance the control that Americans have over their health care*

- Increase individuals' and families' options for choosing health coverage and care that works best for them by eliminating restrictions on coverage and eliminating barriers that exist between patients and health care providers and products.
- Expand individuals' and families' control over their own health care resources, by expanding health savings accounts, reducing third-party payment, and developing price and meaningful quality transparency measures.
- Reform health care subsidies that cause excessive low-value health spending.

#### *Goal 2: Reduce barriers to beneficial competition and create a climate for beneficial innovation*

- Reduce government barriers, rules, and bureaucracy that serve as unnecessary and counterproductive constraints and frustrations for health care providers.
- Reduce government barriers that restrict pharmaceutical and medical device innovation and that protect incumbents from competition.
- Ensure that innovators are developing products to best serve individuals and families, rather than focusing on maximizing reimbursement from government programs.
- Ensure heavily consolidated health care markets are more contestable.